ACS Report Shows Prostate Cancer on the Rise, Cervical Cancer on the Decline
A report from the American Cancer Society reveals trends in cancer incidence and mortality over time and includes projections for 2023.
Diagnosis & Disease Information
Survival Rates High for Children, Teens With Melanoma
Recurrence-free survival and overall survival rates were similar in children and adolescents with melanoma.
Smaller, Rural Oncology Practices Slower to Adopt Approved Immunotherapies
Some oncology practices are less likely than others to adopt immunotherapies within 2 years of regulatory approval, a study suggests.
Immune Checkpoint Inhibitors and CVD Risk in Patients With Melanoma
Immune checkpoint inhibitor therapy may increase the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma.
Noncardiac Biomarkers May Predict Myocarditis From Immune Checkpoint Inhibitor Treatment
Researchers have identified noncardiac biomarkers that may predict myocarditis associated with immune checkpoint inhibitor treatment.
Tumor-Infiltrating Lymphocytes Up PFS in Advanced Melanoma
Longer progression-free survival was seen with tumor-infiltrating lymphocytes than with ipilimumab.
Moderna, Merck Report Data From Trial of mRNA Vaccine in Patients With Melanoma
An mRNA vaccine may reduce the risk of disease recurrence or death in patients with stage III/IV melanoma and a high risk of recurrence after complete resection, according to an announcement from Merck and Moderna.
IMspire150 Update: No OS Improvement With Triplet vs Doublet in BRAF-Mutant Melanoma
A second interim analysis of the IMspire150 trial suggests that adding atezolizumab to vemurafenib and cobimetinib does not improve overall survival in BRAFV600-mutant, advanced melanoma.
2013 to 2017 Saw Significant Drop in US Melanoma Mortality Rates
The introduction of new melanoma treatments coincided with a reduction in the melanoma mortality rate in the United States.
Melanoma Diagnosis Linked to Increased Risk of Prostate Cancer
A more than 2-fold increased risk of prostate cancer was seen for patients whose first melanoma diagnosis was 10 to 15 years before study recruitment.
- Loading...
Loading...
Next post in Skin Cancer
Loading... 
Loading...